VanEck Associates
SRPT icon

VanEck Associates’s Sarepta Therapeutics SRPT Stock Holding History

VanEck Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,096
Closed -$263K – 1473
2026
Q1 		$263K Sell
12,096
-188
-2% -$3.64K ﹤0.01% 1245
2025
Q4 		$264K Buy
12,284
+2,347
+24% +$49.5K ﹤0.01% 1258
2025
Q3 		$191K Sell
9,937
-74,400
-88% -$1.33M ﹤0.01% 1285
2025
Q2 		$1.44M Sell
84,337
-1,581
-2% -$67.5K ﹤0.01% 999
2025
Q1 		$5.48M Buy
85,918
+1,084
+1% +$114K 0.01% 676
2024
Q4 		$10.3M Buy
84,834
+16,658
+24% +$2.04M 0.01% 457
2024
Q3 		$8.85M Sell
68,176
-14,930
-18% -$2.06M 0.01% 483
2024
Q2 		$13.1M Sell
83,106
-3,223
-4% -$414K 0.02% 358
2024
Q1 		$11.2M Buy
86,329
+4,374
+5% +$536K 0.02% 377
2023
Q4 		$7.9M Sell
81,955
-14,510
-15% -$1.39M 0.01% 436
2023
Q3 		$11.7M Sell
96,465
-326
-0.3% -$36.8K 0.03% 319
2023
Q2 		$11.1M Buy
96,791
+4,357
+5% +$562K 0.02% 335
2023
Q1 		$12.7M Buy
92,434
+90,800
+5,557% +$11.8M 0.03% 305
2022
Q4 		$212K Buy
1,634
+480
+42% +$55.6K ﹤0.01% 1083
2022
Q3 		$128K Buy
+1,154
New +$116K ﹤0.01% 1135
2021
Q2 		– Sell
-26,209
Closed -$1.95M – 1309
2021
Q1 		$1.95M Sell
26,209
-70,126
-73% -$6.47M 0.01% 616
2020
Q4 		$16.4M Buy
96,335
+2,439
+3% +$361K 0.05% 229
2020
Q3 		$13.2M Sell
93,896
-12,268
-12% -$1.86M 0.04% 225
2020
Q2 		$17M Buy
106,164
+29,230
+38% +$3.98M 0.06% 196
2020
Q1 		$7.53M Sell
76,934
-23,104
-23% -$2.64M 0.04% 258
2019
Q4 		$12.9M Sell
100,038
-1,314
-1% -$133K 0.05% 225
2019
Q3 		$7.63M Buy
101,352
+4,912
+5% +$580K 0.04% 259
2019
Q2 		$14.7M Sell
96,440
-28,795
-23% -$3.5M 0.07% 189
2019
Q1 		$14.9M Buy
125,235
+910
+0.7% +$117K 0.07% 186
2018
Q4 		$13.6M Buy
124,325
+15,763
+15% +$1.97M 0.07% 202
2018
Q3 		$17.5M Buy
+108,562
New +$14.8M 0.09% 193

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

VanEck Associates's SRPT Position: Q2 2026 in Review

VanEck Associates sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 12,096 shares — an estimated $263K sold.

VanEck Associates first reported a position in SRPT in Q3 2018 and held it in 26 quarters. The position peaked at $17.5M in Q3 2018. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • VanEck Associates reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • VanEck Associates sold 12,096 Sarepta Therapeutics shares in Q2 2026, an estimated $263K.
  • VanEck Associates first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 26 quarters.
  • VanEck Associates's Sarepta Therapeutics position peaked at $17.5M in Q3 2018.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.